Skip to main content

Table 2 Cardiovascular Outcomes at 3 Years

From: New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins

Clinical outcome Atorvastatin (n = 1349) Rosuvastatin (n = 872) P-value
New onset diabetes mellitus 99 (7.5) 70 (9.2) 0.550
MACE 149 (11.0) 91 (10.4) 0.662
All cause of mortality 49 (3.6) 25 (2.9) 0.335
 Cardiac death 19 (1.4) 14 (1.6) 0.710
 Non-cardiac death 30 (2.2) 11 (1.3) 0.103
Any myocardial infarction 30 (2.3) 15 (1.8) 0.409
 STEMI 8 (0.6) 1 (0.1) 0.083
 NSTEMI 22 (1.7) 14 (1.6) 0.956
Any revascularization 98 (7.4) 62 (7.2) 0.892
 TLR 24 (1.9) 21 (2.5) 0.312
 TVR 48 (3.7) 34 (4.0) 0.692
 NTVR 51 (3.9) 31 (3.7) 0.788
Stroke 27 (2.0) 10 (1.2) 0.127
  1. MACE major adverse cardiovascular event, STEMI ST-segment elevation myocardial infarction, NSTEMI Non-ST-segment elevation myocardial infarction, NTVR non-target vessel revascularization, TLR target lesion revascularization, TVR target vessel revascularization